201 related articles for article (PubMed ID: 18282242)
1. Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil.
Guba M; Rentsch M; Wimmer CD; Uemueksuez A; Illner WD; Schönermarck U; Land WG; Jauch KW; Arbogast H
Transpl Int; 2008 Jul; 21(7):637-45. PubMed ID: 18282242
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial.
Arbogast HP; Hoffmann JN; Illner WD; Hillebrand GF; Fischereder M; Jauch KW; Land W
Transplant Proc; 2009; 41(6):2529-32. PubMed ID: 19715968
[TBL] [Abstract][Full Text] [Related]
3. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
4. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
5. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
6. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
Grinyó JM; Gil-Vernet S; Seron D; Hueso M; Fulladosa X; Cruzado JM; Moreso F; Fernandez A; Torras J; Riera L; Castelao AM; Alsina J
Nephrol Dial Transplant; 1998 Oct; 13(10):2601-4. PubMed ID: 9794567
[TBL] [Abstract][Full Text] [Related]
7. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
[TBL] [Abstract][Full Text] [Related]
8. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
9. Kidney graft outcomes in living-related transplantation have improved with substitution of basiliximab and mycophenolate mofetil for antithymocyte globulin and azathioprine: a single center retrospective cohort study.
Imamović G; Zerem E; Osmanović E
Eur J Intern Med; 2010 Dec; 21(6):524-9. PubMed ID: 21111938
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin-inhibitor-sparing immunosuppressive protocols.
Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3729-32. PubMed ID: 16386520
[TBL] [Abstract][Full Text] [Related]
11. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
[TBL] [Abstract][Full Text] [Related]
12. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
14. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
[TBL] [Abstract][Full Text] [Related]
16. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
[TBL] [Abstract][Full Text] [Related]
17. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
18. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab induction in deceased donor kidney transplantation.
Huang E; Cho YW; Hayashi R; Bunnapradist S
Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
[TBL] [Abstract][Full Text] [Related]
20. Comparison of sequential protocol using basiliximab versus antithymocyte globulin with high-dose mycophenolate mofetil in recipients of a kidney graft from an expanded-criteria donor.
Pallet N; Anglicheau D; Martinez F; Mamzer MF; Legendre C; Thervet E
Transplantation; 2006 Mar; 81(6):949-52. PubMed ID: 16570022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
